共 60 条
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
被引:413
作者:
Cherney, David Z. I.
[1
]
Perkins, Bruce A.
[2
]
Soleymanlou, Nima
[3
]
Har, Ronnie
[1
]
Fagan, Nora
[4
]
Johansen, Odd Erik
[5
]
Woerle, Hans-Juergen
[5
]
von Eynatten, Maximilian
[4
]
Broedl, Uli C.
机构:
[1] Univ Toronto, Univ Hlth Network, Toronto Gen Hosp, Div Nephrol, Toronto, ON M5G 2N2, Canada
[2] Univ Toronto, Univ Hlth Network, Div Endocrinol, Toronto, ON M5G 2N2, Canada
[3] Boehringer Ingelheim Canada Ltd Ltee, Burlington, ON, Canada
[4] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
关键词:
Diabetes mellitus;
Systemic blood pressure;
SGLT2;
inhibition;
Empagliflozin;
Hyperglycaemia;
Arterial stiffness;
Heart rate variability;
GLOMERULAR-FILTRATION-RATE;
INTENSIVE GLYCEMIC CONTROL;
BLOOD-PRESSURE;
ENDOTHELIAL FUNCTION;
DOUBLE-BLIND;
WEIGHT-LOSS;
ADD-ON;
SGLT2;
INHIBITORS;
IMPROVES;
METFORMIN;
D O I:
10.1186/1475-2840-13-28
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Background: Individuals with type 1 diabetes mellitus are at high risk for the development of hypertension, contributing to cardiovascular complications. Hyperglycaemia-mediated neurohormonal activation increases arterial stiffness, and is an important contributing factor for hypertension. Since the sodium glucose cotransport-2 (SGLT2) inhibitor empagliflozin lowers blood pressure and HbA1c in type 1 diabetes mellitus, we hypothesized that this agent would also reduce arterial stiffness and markers of sympathetic nervous system activity. Methods: Blood pressure, arterial stiffness, heart rate variability (HRV) and circulating adrenergic mediators were measured during clamped euglycaemia (blood glucose 4-6 mmol/L) and hyperglycaemia (blood glucose 9-11 mmol/L) in 40 normotensive type 1 diabetes mellitus patients. Studies were repeated after 8 weeks of empagliflozin (25 mg once daily). Results: In response to empagliflozin during clamped euglycaemia, systolic blood pressure (111 +/- 9 to 109 +/- 9 mmHg, p = 0.02) and augmentation indices at the radial (-52% +/- 16 to -57% +/- 17, p = 0.0001), carotid (+1.3 +/- 17.0 to -5.7 +/- 17.0%, p < 0.0001) and aortic positions (+0.1 +/- 13.4 to -6.2 +/- 14.3%, p < 0.0001) declined. Similar effects on arterial stiffness were observed during clamped hyperglycaemia without changing blood pressure under this condition. Carotid-radial pulse wave velocity decreased significantly under both glycemic conditions (p = 0.0001), while declines in carotid-femoral pulse wave velocity were only significant during clamped hyperglycaemia (5.7 +/- 1.1 to 5.2 +/- 0.9 m/s, p = 0.0017). HRV, plasma noradrenalin and adrenaline remained unchanged under both clamped euglycemic and hyperglycemic conditions. Conclusions: Empagliflozin is associated with a decline in arterial stiffness in young type 1 diabetes mellitus subjects. The underlying mechanisms may relate to pleiotropic actions of SGLT2 inhibition, including glucose lowering, antihypertensive and weight reduction effects.
引用
收藏
页数:8
相关论文